In several malignant cancers including brain, breast and colon cancers, CD133 has been considered to be one of the putative CSCs marker proteins to identify them as well as tissue-specific SCs such as hematopoietic SCs [45,141,142]. This evidence concerns the gene PROM1 and malignant colon neoplasm.